DUAVEE & BONE LOSS

stand up to
postmenopausal osteoporosis

DUAVEE is for postmenopausal women who have NOT had a hysterectomy (i.e., women with a uterus).

In studies of 1- and 2-years' duration, on average, DUAVEE significantly increased bone mineral density of the total hip and lumbar spine to help prevent postmenopausal osteoporosis.

While you're taking DUAVEE, it may help reduce the chances of developing postmenopausal osteoporosis, a serious bone disease caused by a decrease in bone mineral density, leading to thin, weak bones.

If you use DUAVEE only to prevent osteoporosis due to menopause, talk with your doctor or other healthcare professional (HCP) about whether a different treatment or medicine without estrogens might be better for you.

DUAVEE bone mineral density increase was compared to placebo. Patients also took calcium and vitamin D daily.

 

DUAVEE was evaluated in 2 studies to determine the effects of bazedoxifene/conjugated estrogens combinations on the thickening of the lining of the uterus and the prevention of osteoporosis in postmenopausal women with a uterus. Study 1 compared the effects of DUAVEE vs placebo in 3397 postmenopausal women with a uterus between the ages of 40 and 75 years who were postmenopausal for more than 5 years or for 1-5 years with a risk factor for osteoporosis. The change in lumbar bone mineral density was measured at 2 years of treatment. Study 2 evaluated the prevention of osteoporosis in 590 women who were 1-5 years postmenopausal. Women also took calcium and vitamin D daily.

 

DUAVEE & BONE LOSS

stand up to postmenopausal osteoporosis

DUAVEE is for postmenopausal women who have NOT had a hysterectomy (i.e., women with a uterus).

In studies of 1- and 2-years' duration, on average,DUAVEE significantly increased bone mineral density of the total hip and lumbar spine to help prevent postmenopausal osteoporosis.

While you're taking DUAVEE, it may help reduce the chances of developing postmenopausal osteoporosis, a serious bone disease caused by a decrease in bone mineral density, leading to thin, weak bones.

If you use DUAVEE only to prevent osteoporosis due to menopause, talk with your doctor or other healthcare professional (HCP) about whether a different treatment or medicine without estrogens might be better for you.

DUAVEE bone mineral density increase was compared to placebo. Patients also took calcium and vitamin D daily.

DUAVEE was evaluated in 2 studies to determine the effects of bazedoxifene/conjugated estrogens combinations on the thickening of the lining of the uterus and the prevention of osteoporosis in postmenopausal women with a uterus. Study 1 compared the effects of DUAVEE vs placebo in 3397 postmenopausal women with a uterus between the ages of 40 and 75 years who were postmenopausal for more than 5 years or for 1-5 years with a risk factor for osteoporosis. The change in lumbar bone mineral density was measured at 2 years of treatment. Study 2 evaluated the prevention of osteoporosis in 590 women who were 1-5 years postmenopausal. Women also took calcium and vitamin D daily.

 

*Eligibility required. No membership fees. The Card is not health insurance. The Card will be accepted only at participating pharmacies. Individual savings limited to $70 per monthly prescription or $840 in maximum total savings per calendar year. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card even if you elect to be processed as an uninsured (cash-paying) patient. For any questions, please call 1-866-881-2545, or write Pfizer, Attn: DUAVEE, 235 East 42nd Street, New York, NY 10017. Terms and Conditions apply. Expires 12/31/2021. Visit www.DUAVEE.com for full Terms and Conditions. Pfizer reserves the right to rescind, revoke or amend this offer without notice.

Are you feeling the heat? Learn about an Rx treatment that can help with moderate-to-severe hot flashes due to menopause: www.duavee.com >>

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION & INDICATIONS

Do not take additional estrogens, progestins, or estrogen agonists/antagonists while taking DUAVEE® (conjugated estrogens/bazedoxifene).

Using estrogen may increase your chance of getting cancer of the uterus. Report any unusual vaginal bleeding right away while taking DUAVEE. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus. A healthcare provider should check unusual vaginal bleeding to find the cause.

Do not use estrogens to prevent heart disease, heart attacks, strokes, or dementia.

Estrogens may increase the chance of getting blood clots or strokes.

Using estrogens may increase the chance of getting dementia, based on a study of women 65 years of age or older.

You and your healthcare provider should talk regularly about whether you still need treatment with DUAVEE.

Do not use DUAVEE if you: have or had blood clots; are allergic to any of its ingredients; have unusual vaginal bleeding; have or had certain cancers (eg, uterine or breast), liver problems, or bleeding disorders; or are pregnant.

The use of estrogen alone has been reported to result in an increase in abnormal mammograms requiring further evaluation. The effect of treatment with DUAVEE on the risk of breast and ovarian cancer is unknown.

Estrogens increase the risk of gallbladder disease. Discontinue estrogen if loss of vision, pancreatitis, or liver problems occur. If you take thyroid medication, consult your healthcare provider, as use of estrogens may change the amount needed.

The most common side effects include muscle spasms, nausea, diarrhea, upset stomach, abdominal pain, throat pain, dizziness, and neck pain.

 

INDICATIONS

DUAVEE is used after menopause for women with a uterus to reduce moderate-to-severe hot flashes and to help reduce the chances of developing osteoporosis.

If you use DUAVEE only to prevent osteoporosis due to menopause, talk with your healthcare provider about whether a different treatment or medicine without estrogens might be better for you. DUAVEE should be taken for the shortest time possible and only for as long as treatment is needed. You and your healthcare provider should talk regularly about whether you still need treatment with DUAVEE.

Please see Full Prescribing Information, including BOXED WARNING and Patient Information.

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (U.S. only). If you prefer, you may contact the U.S. Food and Drug Administration (FDA) directly. Visit http://www.fda.gov/MedWatch or call 1-800-FDA-1088.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

Doctors may recommend alternative treatment options to their patients.

Back to Top